Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R L Medcalf

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
Biochimica Et Biophysica Acta|September 27, 2000
The novel anti-tumour agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activityA E Dear, R L Medcalf
The Journal of Biological Chemistry|March 30, 2001
Plasminogen activator inhibitor type 2 contains mRNA instability elements within exon 4 of the coding region. Sequence homology to coding region instability determinants in other mRNAsM J Tierney, R L Medcalf
Arthritis and Rheumatism|November 1, 1986
Human synovial fibroblasts produce urokinase-type plasminogen activatorR L Medcalf, J A Hamilton
Molecular Endocrinology (Baltimore, Md.)|December 1, 1991
Regulation of human tissue-type plasminogen activator gene transcription by epidermal growth factor and 3',5'-cyclic adenosine monophosphateR L Medcalf, W D Schleuning
Journal of Thrombosis and Haemostasis : JTH|August 22, 2014
Is plasminogen activator inhibitor type 2 really a plasminogen activator inhibitor after all?E E Gardiner, R L Medcalf
European Journal of Biochemistry|April 2, 1998
The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic moleculeA E Dear, R L Medcalf
Behavioural Brain Research|February 28, 2015
Evaluation of gait impairment in mice subjected to craniotomy and traumatic brain injuryM Sashindranath, M Daglas, R L Medcalf
FEBS Letters|October 6, 2000
Overexpression of a dominant negative CREB protein in HT-1080 cells selectively disrupts plasminogen activator inhibitor type 2 but not tissue-type plasminogen activator gene expressionM Costa, Y Shen, R L Medcalf
Nucleic Acids Research|March 17, 1999
An AU-rich sequence in the 3'-UTR of plasminogen activator inhibitor type 2 (PAI-2) mRNA promotes PAI-2 mRNA decay and provides a binding site for nuclear HuRF Maurer, M Tierney, R L Medcalf
Journal of Thrombosis and Haemostasis : JTH|April 11, 2018
Magnetic fibrinolysis: putting the therapeutic wheels in a corkscrew motionR L Medcalf, C E Hagemeyer, K Alt
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Biochimica Et Biophysica Acta|September 27, 2000
The novel anti-tumour agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activityA E Dear, R L Medcalf
The Journal of Biological Chemistry|March 30, 2001
Plasminogen activator inhibitor type 2 contains mRNA instability elements within exon 4 of the coding region. Sequence homology to coding region instability determinants in other mRNAsM J Tierney, R L Medcalf
Arthritis and Rheumatism|November 1, 1986
Human synovial fibroblasts produce urokinase-type plasminogen activatorR L Medcalf, J A Hamilton
Molecular Endocrinology (Baltimore, Md.)|December 1, 1991
Regulation of human tissue-type plasminogen activator gene transcription by epidermal growth factor and 3',5'-cyclic adenosine monophosphateR L Medcalf, W D Schleuning
Journal of Thrombosis and Haemostasis : JTH|August 22, 2014
Is plasminogen activator inhibitor type 2 really a plasminogen activator inhibitor after all?E E Gardiner, R L Medcalf
European Journal of Biochemistry|April 2, 1998
The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic moleculeA E Dear, R L Medcalf
Behavioural Brain Research|February 28, 2015
Evaluation of gait impairment in mice subjected to craniotomy and traumatic brain injuryM Sashindranath, M Daglas, R L Medcalf
FEBS Letters|October 6, 2000
Overexpression of a dominant negative CREB protein in HT-1080 cells selectively disrupts plasminogen activator inhibitor type 2 but not tissue-type plasminogen activator gene expressionM Costa, Y Shen, R L Medcalf
Nucleic Acids Research|March 17, 1999
An AU-rich sequence in the 3'-UTR of plasminogen activator inhibitor type 2 (PAI-2) mRNA promotes PAI-2 mRNA decay and provides a binding site for nuclear HuRF Maurer, M Tierney, R L Medcalf
Journal of Thrombosis and Haemostasis : JTH|April 11, 2018
Magnetic fibrinolysis: putting the therapeutic wheels in a corkscrew motionR L Medcalf, C E Hagemeyer, K Alt
Pageof 7